Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and WBRT in SCLC brain metastases
NCT06611657Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in small cell lung cancer (SCLC), brain metastasis (BM), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Aug 2021; status: active, not recruiting.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)brain metastasis (BM)
Beyond the preview
Go deeper on NCT06611657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611657.